Q2 FY2026 · ended Jun 30, 2026 · Revenue $9.13M, -1.1% YoY · Filed Aug 10, 2026
Interpace Biosciences, Inc. (IDXG) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $9.1 million and net income of $158,000. Free cash flow was $41,000. As of Jun 30, 2026 it held $2.7 million in cash and investments and $974,000 in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- IDXG (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Parsippany, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1054102
- Former names
- Interpace Diagnostics Group, Inc. (until Nov 1, 2019); PDI INC (until Dec 22, 2015); PROFESSIONAL DETAILING INC (until Nov 13, 2002)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $9.1M | $9.0M | $9.2M | $8.8M | $9.2M |
| Operating income | $321,000 | $1.1M | $1.6M | $1.1M | -$468,000 |
| Net income | $158,000 | $721,000 | $22.7M | $911,000 | -$640,000 |
| Diluted EPS | $0.01 | $0.03 | $0.82 | $0.03 | -$0.14 |
| Operating cash flow | $98,000 | $283,000 | $2.1M | $1.9M | $520,000 |
| Free cash flow | $41,000 | $142,000 | $2.1M | $1.8M | $347,000 |
| Total assets | $34.5M | $33.4M | $33.8M | $12.0M | $12.3M |
| Total liabilities | $11.3M | $10.3M | $11.5M | $12.3M | $13.5M |
| Stockholders' equity | $23.2M | $23.1M | $22.4M | -$298,000 | -$1.2M |
| Cash and investments | $2.7M | $2.6M | $2.5M | — | $502,000 |
| Total debt | $974,000 | $1.1M | $1.2M | $1.3M | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 27, 2026 | Aug 27, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Aug 26, 2026 | Aug 20, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 21, 2026 | Aug 20, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
All 1001 Interpace Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.